Precision medicine relies on accurate tools to track tumor evolution in real-time. Recent research emphasizes that ctDNA monitoring endometrial cancer provides a minimally invasive solution for tracking disease dynamics in patients with advanced stages. This approach allows clinicians to observe how tumors change and develop therapeutic resistance over time. Consequently, liquid biopsies are becoming essential components for managing advanced gynecological malignancies in modern oncology.

A retrospective study recently analyzed the performance of an off-the-shelf targeted Next-Generation Sequencing (NGS) panel. Researchers compared this tumor-agnostic method with a tumor-informed digital droplet PCR (ddPCR) approach in a cohort of 18 patients. Notably, NGS detected circulating tumor DNA in over 60% of plasma samples. However, ddPCR demonstrated a higher positivity rate of approximately 72% in paired samples. The overall concordance between these two methods reached 65.7%, indicating fair agreement between the technological platforms.

Improving Precision through ctDNA Monitoring Endometrial Cancer

The study highlights how the cfDNA-NGS panel identifies a broad spectrum of genetic alterations. Specifically, the panel revealed relapse-specific mutations that serve as clear indicators of clonal evolution. This information is vital because it helps doctors understand how the cancer adapts to specific treatments. Moreover, ctDNA levels correlate closely with disease progression and therapeutic response. Therefore, longitudinal tracking serves as a powerful indicator of a patient’s current clinical status.

Despite these benefits, certain technical and biological limitations exist. For instance, assay sensitivity for low-frequency variants remains lower in NGS compared to the targeted ddPCR approach. Furthermore, cases involving brain metastases showed limited ctDNA detection in the systemic circulation. This occurs because the blood-brain barrier often restricts the entry of tumor DNA into the peripheral blood. Additionally, clinicians must interpret results carefully to account for clonal hematopoiesis, which can sometimes mimic tumor-derived mutations.

In conclusion, tumor-agnostic monitoring offers significant utility for managing advanced cases. While ddPCR remains highly sensitive for specific known targets, NGS provides a more comprehensive view of the evolving mutational landscape. Careful interpretation of assay quality and biological factors ensures that clinicians make informed treatment decisions. Ultimately, these findings support the growing role of liquid biopsy in improving outcomes for patients with endometrial cancer.

FAQs

How does NGS compare to ddPCR in endometrial cancer monitoring?

Research indicates that tumor-informed ddPCR generally provides higher sensitivity for specific low-frequency variants compared to off-the-shelf NGS panels. However, NGS offers the advantage of identifying a broader range of new mutations and tracking clonal evolution throughout the disease course.

What factors limit the sensitivity of ctDNA detection?

Detection sensitivity can be affected by the presence of brain metastases, which often release less DNA into the systemic circulation. Additionally, biological factors like clonal hematopoiesis and the technical limits of the NGS panel can lead to discordant or false-negative results.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult a qualified healthcare provider for any medical concerns or before making changes to your treatment plan. Refer to the latest local and national guidelines for clinical practice.

References

Casas-Arozamena C et al. Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off-the-shelf targeted NGS panel. Mol Oncol. 2026 Apr 28. doi: 10.1002/1878-0261.70246. PMID: 42047179.

Shen Y, Shi R, Zhao R, Wang H. Clinical application of liquid biopsy in endometrial carcinoma. J Cancer Res Clin Oncol. 2023 Feb 9;149(11):9445-9459.

Soumerai TE, et al. ctDNA Detects Endometrial Cancer Recurrence Risk Beyond Standard Markers. Gynecologic Oncology. 2024 Feb 9.